Earnings Scheduled For February 28, 2022
Companies Reporting Before The Bell
• Lexicon Pharmaceuticals (NASDAQ:LXRX) is estimated to report earnings for its fourth quarter.
The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight
Biopharma stocks lock-stepped with the broader market in the week ending Feb. 25 before finishing higher. The trajectory was the same, with the sector declining in the first two sessions of the holiday-shortened week before making a comeback.
Acadia Resubmits Pimavanserin US Application For Expanded Use In Alzheimer’s Psychosis
Acadia Pharmaceuticals Inc (NASDAQ: ACAD) has
Expert Ratings For ACADIA Pharmaceuticals
ACADIA Pharmaceuticals (NASDAQ:ACAD) has observed the following analyst ratings within the last quarter:
10 Health Care Stocks With Whale Alerts In Today’s Session
This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Acadia Pharmaceuticals And Stoke Therapeutics Announce Collaboration To Pursue Multiple RNA-based Treatments For Severe And Rare Genetic Neurodevelopmental Diseases
– Establishes co-development and co-commercialization agreement for Stoke’s SYNGAP1 preclinical program
– Acadia receives exclusive worldwide licenses for two additional preclinical programs: Rett
$1000 Invested In This Stock 10 Years Ago, Would Be Worth This Much
ACADIA Pharmaceuticals (NASDAQ:ACAD) has outperformed the market over the past 10 years by 22.05% on an annualized basis.
5 Beaten Down Biotech Stocks That Could Bounce Big In 2022
Biotech stocks remain poised to eke out modest gains for 2021 after the stellar gains of the previous year. COVID-19 drug and vaccine developers experienced volatility throughout 2021 amid delays in programs and the reemergence of variant strains.
12 Health Care Stocks Moving In Thursday’s After-Market Session
Gainers
Tempest Therapeutics (NASDAQ:TPST) shares increased by 8.19% to $6.6 during Thursday's after-market session. The company's market cap stands at $45.6 million.